<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35313908</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>23</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>25</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1749-8090</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Mar</Month>
              <Day>21</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of cardiothoracic surgery</Title>
          <ISOAbbreviation>J Cardiothorac Surg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Complete recovery of deep venous thrombosis from Coombs (+) thrombotic thrombocytopenic purpura: case report.</ArticleTitle>
        <Pagination>
          <StartPage>43</StartPage>
          <MedlinePgn>43</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">43</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13019-022-01789-8</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Acute thrombotic thrombocytopenic purpura (TTP) is an aggressive thrombotic microangiopathy that if not treated, can have a 90% mortality rate. Timely, extensive plasma exchange (PEX) has been indicated to reduce the mortality rate to &lt; 10%, but its side effects are not well-known. We present here a case of a patient presented with Comb (+) TTP and developed catheter-associated deep vein thrombosis (DVT).</AbstractText>
          <AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">A 27-year-young man presented with persistent thrombocytopenia and Coombs positive anemia was firstly diagnosed with Evans syndrome. However, he was refractory to a methylprednisolone pulse therapy with a combination of platelet transfusion and eventually developed microangiopathy of central nerve system. Several pathological manifestations of the disease were prevented by PEX. The immediate start of PEX (1500 mL/d) induced a complete remission of acquired TTP and disappearance of neurological signs and symptoms. However, external iliac and femoro-popliteal venous thrombosis was diagnosed subsequently, inferior vena cava filter (IVC) filter was immediately implanted accompanied with anticoagulation therapy. Meanwhile, PEX session was sustained as well as oral anticoagulant (rivaroxaban). 14 days later, the patient got full recovery.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Catheter-related DVT under the setting of TTP should be cautious. It is necessary to start anticoagulation and antiplatelet therapy for thrombosis early, especially in such cases when PLT count &gt; 50 × 10<sup>9</sup>/L.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Mi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yin</LastName>
            <ForeName>Jie</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Shandong Provincial Qianfoshan Hospital, the First Hospital Affiliated With Shandong First Medical University, Jinan, Shandong, China. yjangelsmile@126.com.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Cardiology, Shandong Province Qianfushan Hospital, Shandong University, Jinan, 250014, China. yjangelsmile@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>21</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Cardiothorac Surg</MedlineTA>
        <NlmUniqueID>101265113</NlmUniqueID>
        <ISSNLinking>1749-8090</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010951" MajorTopicYN="N">Plasma Exchange</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017713" MajorTopicYN="N">Platelet Transfusion</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011697" MajorTopicYN="Y">Purpura, Thrombotic Thrombocytopenic</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Deep vein thrombosis</Keyword>
        <Keyword MajorTopicYN="N">Plasma exchange</Keyword>
        <Keyword MajorTopicYN="N">Thrombotic thrombocytopenic purpura</Keyword>
      </KeywordList>
      <CoiStatement>Authors declare that they have no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35313908</ArticleId>
        <ArticleId IdType="pmc">PMC8935836</ArticleId>
        <ArticleId IdType="doi">10.1186/s13019-022-01789-8</ArticleId>
        <ArticleId IdType="pii">10.1186/s13019-022-01789-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654–666. doi: 10.1056/NEJMra1312353.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1312353</ArticleId>
            <ArticleId IdType="pubmed">25119611</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chapman K, Seldon M, Richards R. Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13. Semin Thromb Hemost. 2012;38:47–54. doi: 10.1055/s-0031-1300951.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0031-1300951</ArticleId>
            <ArticleId IdType="pubmed">22314603</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>George JN, Sandler SA, Stankiewicz J. Management of thrombotic thrombocytopenic purpura without plasma exchange: the Jehovah's Witness experience. Blood Adv. 2017;1:2161–2165. doi: 10.1182/bloodadvances.2017012351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2017012351</ArticleId>
            <ArticleId IdType="pmc">PMC5737137</ArticleId>
            <ArticleId IdType="pubmed">29296863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ. British Committee for Standards in H: guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol. 2012;158:323–335. doi: 10.1111/j.1365-2141.2012.09167.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2012.09167.x</ArticleId>
            <ArticleId IdType="pubmed">22624596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Froissart A, Buffet M, Veyradier A, Poullin P, Provot F, Malot S, Schwarzinger M, Galicier L, Vanhille P, Vernant JP, et al.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40:104–111. doi: 10.1097/CCM.0b013e31822e9d66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CCM.0b013e31822e9d66</ArticleId>
            <ArticleId IdType="pubmed">21926591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dimopoulou D, Dimosiari A, Mandala E, Dimitroulas T, Garyfallos A. Autoimmune thrombotic thrombocytopenic purpura: two rare cases associated with juvenile idiopathic arthritis and multiple sclerosis. Front Med (Lausanne) 2017;4:89. doi: 10.3389/fmed.2017.00089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fmed.2017.00089</ArticleId>
            <ArticleId IdType="pmc">PMC5522843</ArticleId>
            <ArticleId IdType="pubmed">28791286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang C, Chen XH, Zhang X. Quick development and sudden death: evans syndrome followed by thrombotic thrombocytopenic purpura. Am J Emerg Med. 2014;32(1156):e1153–e1154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24686025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1:590–600. doi: 10.1182/bloodadvances.2017005124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2017005124</ArticleId>
            <ArticleId IdType="pmc">PMC5728353</ArticleId>
            <ArticleId IdType="pubmed">29296701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Howard MA, Williams LA, Terrell DR, Duvall D, Vesely SK, George JN. Complications of plasma exchange in patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Transfusion. 2006;46:154–156. doi: 10.1111/j.1537-2995.2006.00687.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1537-2995.2006.00687.x</ArticleId>
            <ArticleId IdType="pubmed">16398746</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oshima T, Ikutomi M, Shinohara H, Ishiwata J, Fukino K, Amaki T, Nakamura F. Acute myocardial infarction caused by thrombotic microangiopathy complicated with myelodysplastic syndrome. Int Heart J. 2016;57:634–636. doi: 10.1536/ihj.16-100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1536/ihj.16-100</ArticleId>
            <ArticleId IdType="pubmed">27628419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003;348:1123–1133. doi: 10.1056/NEJMra011883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra011883</ArticleId>
            <ArticleId IdType="pubmed">12646670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rottenstreich A, Kalish Y, Tvito A, Hauschner H, Arad A. Acquired thrombotic thrombocytopenic purpura in pregnancy: the role of placental and breast-milk mediated transfer of ADAMTS13-autoantibodies. Thromb Res. 2017;156:80–81. doi: 10.1016/j.thromres.2017.06.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2017.06.005</ArticleId>
            <ArticleId IdType="pubmed">28605658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakao H, Ishiguro A, Ikoma N, Nishi K, Su C, Nakadate H, Kubota M, Hayakawa M, Matsumoto M. Acquired idiopathic thrombotic thrombocytopenic purpura successfully treated with intravenous immunoglobulin and glucocorticoid: a case report. Medicine (Baltimore) 2017;96:e6547. doi: 10.1097/MD.0000000000006547.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MD.0000000000006547</ArticleId>
            <ArticleId IdType="pmc">PMC5411206</ArticleId>
            <ArticleId IdType="pubmed">28383422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jestin M, Benhamou Y, Schelpe A-S, Roose E, Galicier L, Girault S, et al.  Rituximab prevents long-term relapses in TTP. Blood. 2018;132:2210. doi: 10.1182/blood-2018-04-840090.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2018-04-840090</ArticleId>
            <ArticleId IdType="pubmed">30201758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thumma S, Idrees S, Phuyal P, Manchala V, Mattana J. When the standard treatment fails: rituximab therapy for refractory TTP. Am J Ther. 2019;26:e552–e553. doi: 10.1097/MJT.0000000000000808.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MJT.0000000000000808</ArticleId>
            <ArticleId IdType="pubmed">29965802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knobl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, et al.  Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374:511–522. doi: 10.1056/NEJMoa1505533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1505533</ArticleId>
            <ArticleId IdType="pubmed">26863353</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
